Clin2
NCT04731155Possibly a fitRecruiting

Test early PCSK9 medicine to prevent heart problems after a heart attack

Early PCSK9 Inhibitor on Ventricular Remodling

Part of Heart & circulation clinical trials.

This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
20 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You’re between 18 and 79 years old
  • You recently had a heart-artery procedure (PCI) with a drug-eluting stent after an acute heart attack
  • Your only blocked culprit artery was the LAD (left anterior descending) artery
  • You understand the study and agree by signing informed consent
  • You do not plan another revascularization (repeat artery-opening procedure) in the next 6 months
  • You have not had a prior revascularization procedure before this heart attack

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05292404Recruiting· Phase 4
PCSK9 medicine soon after heart attack to protect the heart

This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.

Shanghai, Shanghai Municipality
NCT07208006Recruiting
Early cholesterol-lowering drug after heart attack

This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.

Shanghai, Shanghai Municipality
NCT06863545Recruiting
PCSK9 Inhibitors for High-Risk Coronary Plaques on CT

This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.

Hangzhou, Zhejiang
NCT07002476Recruiting· Phase 3
Early aggressive cholesterol-lowering after stroke with clot removal

This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.

Shanghai
NCT06854523Not yet recruiting
Early PCSK9 inhibitor after heart attack for other artery blockages

This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.

Beijing, Beijing Municipality
NCT06791031Not yet recruiting
PCSK9 inhibitor to stabilize artery plaques after heart attack

This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.

Hear when a new Early PCSK9 Inhibitor on Ventricular Remodling trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.